摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3-chloro-4-methoxyphenyl)cyclopropane-1-carboxylic acid | 936728-03-9

中文名称
——
中文别名
——
英文名称
1-(3-chloro-4-methoxyphenyl)cyclopropane-1-carboxylic acid
英文别名
1-(3-chloro-4-methoxyphenyl)cyclopropanecarboxylic acid
1-(3-chloro-4-methoxyphenyl)cyclopropane-1-carboxylic acid化学式
CAS
936728-03-9
化学式
C11H11ClO3
mdl
——
分子量
226.66
InChiKey
IJNNWPMZHGIFOW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US20150231142A1
    公开(公告)日:2015-08-20
    The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
    本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物(A式、B式、C式或D式)的药物组合物。该发明还涉及这些药物配方,以及使用这些组合物治疗CFTR介导的疾病,特别是囊性纤维化的方法。
  • COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
    申请人:Van Goor Fredrick F.
    公开号:US20110098311A1
    公开(公告)日:2011-04-28
    The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
    本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物(A式、B式、C式或D式)的药物组合物。该发明还涉及这些药物配方,以及使用这些组合物治疗CFTR介导的疾病,特别是囊性纤维化的方法。
  • Modulators of ATP-binding cassette transporters
    申请人:Hadida Ruah S. Sara
    公开号:US20070244159A1
    公开(公告)日:2007-10-18
    Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    本发明的化合物及其药学上可接受的组合物,可用作调节ATP结合盒(“ABC”)转运蛋白或其片段的工具,包括囊性纤维化跨膜传导调节蛋白(“CFTR”)。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
  • [EN] HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLYLE ET LEUR UTILISATION COMME MODULATEURS DE RÉCEPTEURS DE LA PROSTAGLANDINE D2
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2013093842A1
    公开(公告)日:2013-06-27
    The present invention relates to phenyl-substituted heterocyclyl derivatives of the formula (I) wherein Z, n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    本发明涉及式(I)的苯基取代杂环基衍生物,其中Z、n、m、R1、R2、R3、R4、R5、R6、R7和R8如描述中所述,并且它们作为前列腺素受体调节剂的用途,尤其作为前列腺素D2受体调节剂,在治疗各种前列腺素介导的疾病和紊乱中的用途,以及含有这些化合物的药物组合物和其制备方法。
  • Indole derivatives as CFTR modulators
    申请人:Ruah Sara S. Hadida
    公开号:US20090131492A1
    公开(公告)日:2009-05-21
    Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    本发明的化合物及其药学上可接受的组合物,可用作ATP结合盒(“ABC”)转运蛋白或其片段的调节剂,包括囊性纤维化跨膜传导调节因子(“CFTR”)。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
查看更多